Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis.

Liu, Yinghui; Ren, Zuen; Wang, Jinghui; Zhang, Shucai

Liu, Yinghui; Ren, Zuen; Wang, Jinghui; Zhang, Shucai.

Afiliación

Liu Y; Department of Oncology Beijing Chest Hospital, Beijing Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing China.
Ren Z; Department of Thoracic Surgery Beijing Chest Hospital, Beijing Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing China.
Wang J; Department of Oncology Beijing Chest Hospital, Beijing Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing China.
Zhang S; Department of Oncology Beijing Chest Hospital, Beijing Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing China.

Thorac Cancer ; 7(4): 406-14, 2016 Jul.

Article en En | MEDLINE | ID: mdl-27385982

Palabras clave

EGFR mutation; EGFRTKI; NSCLC; metaanalysis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Systematic_reviews Idioma: En Revista: Thorac Cancer Año: 2016 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google